Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending August 2, 2018. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure details as of July 31, 2018:
- Issued Share Capital: 5,374,609,360 Ordinary Shares of 25 pence each.
- Treasury Shares: 414,605,950 Ordinary Shares held in Treasury.
- Total Voting Rights: 4,960,003,410.
Material Changes
The filing text does not provide comparative data against a prior period to identify material changes in share capital or voting rights.
Guidance, Outlook, and Risks
The document contains no management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. Its sole purpose is to establish the denominator for shareholder notification calculations under FCA rules.
Investor Verification Checklist
- Verify the total number of voting rights (4,960,003,410) against the latest shareholder register.
- Confirm the count of Treasury Shares (414,605,950) to ensure accurate calculation of free float.
- Check subsequent filings for any changes to the issued share capital or voting rights structure.